$SLNO

Pomerantz LLP sues Soleno Therapeutics ($SLNO) over alleged securities fraud as stock plummets 39% following DCCR safety concerns and patient death disclosure. Lead Plaintiff deadline: May 5, 2026.

Robbins LLP files class action against $SLNO over safety concerns regarding its Prader-Willi syndrome drug, following critical exposé and patient death disclosure.

Class action lawsuit filed against $SLNO alleging fraud over PWS drug DCCR. Safety concerns, patient death, and commercial disruption emerged in 2025.

Rosen Law Firm files class action against $IBRX, alleging founder Patrick Soon-Shiong overstated Anktiva capabilities, misleading investors about company prospects.

Securities class action filed against $SLNO over alleged false statements regarding safety risks in Phase 3 trial for Prader-Willi syndrome treatment. Lead plaintiff deadline: May 5, 2026.

Four public companies face securities fraud class actions alleging misrepresentations in operational performance, clinical trials, and financial reporting. Lead plaintiff deadlines: May 5-8, 2026.

Portnoy Law Firm sues Soleno Therapeutics for allegedly concealing DCCR safety risks in Phase 3 trials, citing 27% stock drop on November 4, 2025.

Securities lawsuit alleges $SLNO concealed safety concerns about DCCR, its only commercial product for Prader-Willi syndrome treatment, ahead of May 5, 2026 lead plaintiff deadline.

Soleno Therapeutics faces securities lawsuit alleging undisclosed safety risks in its sole commercial product DCCR. Investors have until May 5, 2026 to seek lead plaintiff status.

Law firm Bernstein Liebhard files securities fraud class action against $SLNO, citing alleged misrepresentations regarding Phase 3 DCCR clinical trial program.

Class action lawsuit filed against $SLNO alleging failure to disclose safety concerns about DCCR drug candidate, including fluid retention issues in clinical trials.

$SLNO investors urged to join class action over undisclosed DCCR safety concerns; May 5, 2026 deadline.

Soleno Therapeutics faces class action lawsuit over alleged failure to disclose safety issues with drug DCCR, following 12-27% stock declines from August-September 2025 revelations.

Law firm investigates securities fraud claims against ASP Isotopes, Integer Holdings, Molina Healthcare, and Soleno Therapeutics for alleged misstatements regarding technology, competitive position, medical costs, and drug safety.

Soleno Therapeutics faces securities lawsuit after hyperphagia drug VYKAT XR launch falters amid safety concerns, driving shares down 40% since August short seller report.

Soleno Therapeutics ($SLNO) faces class action lawsuit alleging executives failed to disclose material safety concerns with its lead drug DCCR, with lead plaintiff deadline set for May 5, 2026.

Soleno Therapeutics faces securities fraud lawsuit over alleged safety misstatements in DCCR clinical trial. Stock fell 26% following August short-seller report.

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.

Soleno Therapeutics faces class action lawsuit over DCCR safety concealment claims, with investors suffering significant losses following critical short-seller report and patient death disclosure.

Four public companies face securities fraud investigations alleging misrepresentation of core operations, product safety, and regulatory compliance.